Idorsia Ltd (SWX:IDIA)
2.565
-0.100 (-3.75%)
Aug 14, 2025, 4:45 PM CET
Idorsia Revenue
Idorsia had revenue of 72.24M CHF in the quarter ending June 30, 2025, with 341.89% growth. This brings the company's revenue in the last twelve months to 217.22M, up 69.92% year-over-year. In the year 2024, Idorsia had annual revenue of 112.51M, down -26.17%.
Revenue (ttm)
217.22M
Revenue Growth
+69.92%
P/S Ratio
2.50
Revenue / Employee
334.19K
Employees
650
Market Cap
543.89M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 112.51M | -39.88M | -26.17% |
Dec 31, 2023 | 152.39M | 55.28M | 56.93% |
Dec 31, 2022 | 97.10M | 61.75M | 174.70% |
Dec 31, 2021 | 35.35M | -36.41M | -50.74% |
Dec 31, 2020 | 71.76M | 47.94M | 201.26% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Roche Holding AG | 63.49B |
Novartis AG | 43.89B |
Lonza Group AG | 7.09B |
Alcon | 8.77B |
Galderma Group AG | 3.73B |
Sandoz Group AG | 8.42B |
Straumann Holding AG | 2.58B |
Sonova Holding AG | 3.87B |
Idorsia News
- 3 days ago - Idorsia publishes interim results of repurchase offer for its 2025 and 2028 convertible bonds - GlobeNewsWire
- 14 days ago - Idorsia Ltd (IDRSF) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 15 days ago - Idorsia Ltd 2025 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 15 days ago - Strong sales acceleration of QUVIVIQ drives Idorsia toward profitability – H1 2025 results - GlobeNewsWire
- 21 days ago - Invitation to Idorsia's HY 2025 Financial Reporting webcast and conference call with our new CEO Srishti Gupta - GlobeNewsWire
- 6 weeks ago - A factory in a lab: Idorsia's breakthrough synthetic glycan vaccine platform validated for the first time in humans - GlobeNewsWire
- 7 weeks ago - Idorsia launches repurchase offer for its 2025 and 2028 convertible bonds - GlobeNewsWire
- 2 months ago - Idorsia announces the appointment of Srishti Gupta, MD as CEO to ensure the long-term success of Idorsia - GlobeNewsWire